Loperamide abuse

November 2014
Reactions Weekly;Nov2014, Vol. 1529 Issue 1, p132
An abstract of the article "Cardiac conduction disturbance after loperamide abuse" by J. M. Marraffa and colleagues is presented.


Related Articles

  • Going slowly. Douglas, Colin // BMJ: British Medical Journal (International Edition);10/03/98, Vol. 317 Issue 7163, p955 

    Focuses on an individual's recollection of a teacher who had supraclavicular node, with emphasis on malignant deaths. Information on the significance of the treatment for the node; Insight into the sick leave taken by the individual; Details on open discussions about malignant deaths.

  • Selecting the lead.  // RN;Sep79, Vol. 42 Issue 9, p38 

    Discusses the use of lead in monitoring a patient's rhythm and heart conduction system. Benefits of using Lead II; Description of the modified lead III.

  • 2nd Degree AV Block, Mobitz Type II? Grauer, Ken // Internal Medicine Alert;7/15/2011 Supplement, p104 

    The article discusses the rhythm in the 2nd degree atrioventricular (AV) Block, Mobitz Type II in echocardiography and the classification between Mobitz I and Mobitz II 2nd degree AV block which are divided into three degrees based on severity of the conduction disturbance.

  • Abnormalities of cardiac conduction in diabetics. Blandford, R.L.; Burden, A.C. // British Medical Journal (Clinical Research Edition);12/15/1984, Vol. 289 Issue 6459, p1659 

    Examines the cardiac conduction abnormalities of diabetics. Increase of vulnerability to the patchy fibrotic process; Prevalence of atrioventricular and right bundle branch block; Presence of excessive fibrosis and capillary aneurysms.

  • Is there a molecular explanation of heart rhythm? Noble, Denis // BMJ: British Medical Journal (International Edition);05/10/97, Vol. 314 Issue 7091, p1380 

    Presents an answer to the question of whether there is a molecular explanation for heart rhythm. Generation of heart rhythm as a good example of a physiological function that cannot be explained at the molecular level; Reasons why cardiac rhythm should be studied at a cellular level.

  • Citalopram: dose-related cardiac risk.  // WHO Drug Information;2011, Vol. 25 Issue 4, p358 

    No abstract available.

  • Outcomes of small right ventricle to pulmonary artery conduits.  // Cardiology in the Young;May2006 Supplement, Vol. 16 Issue S2, p20 

    The article presents the abstract "Outcomes of small right ventricle to pulmonary artery conduits," by R. B. M. Hosein, S. Laker, J. Stickley, D. J. Barron and W. J. Brawn.

  • Heart at Work.  // Scholastic News -- Edition 3;02/19/2001, Vol. 57 Issue 18, p3 

    Discusses how a heart works and how to keep it healthy and strong.

  • Concentrations of Fluoroalkanes Associated With Cardiac Conduction System Toxicity. Flowers, Nancy C.; Hand, R. Chris; Horan, Leo G. // Archives of Environmental Health;Jul75, Vol. 30 Issue 7, p353 

    Analyzes the association of fluoroalkanes concentrations with cardiac conduction system toxicity. Occurrence of a concentration of exactly 15 percent, minimal sinus slowing; Effect of concentration ranges between 17.5 percent and 21 percent; Mode of death among animals.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics